Evidence map›Paper›PMID 30069487›Full record

ArticleJournal of immunology research2018

Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis Patients.

Mamiko Niki, Takashi Yoshiyama, Yuji Miyamoto, Masao Okumura, Makoto Niki, Ken-Ichi Oinuma, Yukihiro Kaneko, Sohkichi Matsumoto, Yuka Sasaki, Hideo Ogata and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Evaluation of cytokine profiles related toFrontiers in immunology · 2024
    Article
  2. Article
  3. Predicted Structural Variability ofFrontiers in microbiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Mamiko NikiDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, Japan.
Takashi YoshiyamaDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, Japan.
Yuji MiyamotoDepartment of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Aoba, Higashi-Murayama, Tokyo 189-0002, Japan.
Masao OkumuraDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, Japan.
Makoto NikiDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, Japan.
Ken-Ichi OinumaDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, Japan.
Yukihiro KanekoDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, Japan.
Sohkichi MatsumotoDepartment of Bacteriology, Niigata University Graduate School of Medicine, Niigata 951-8510, Japan.
Yuka SasakiDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, Japan.
Hideo OgataDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, Japan.
Hajime GotoDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, Japan.
Shoji KudohDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, Japan.
Yoshihiko HoshinoDepartment of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Aoba, Higashi-Murayama, Tokyo 189-0002, Japan.ORCID 0000-0002-3132-0715
Japan Anti Tuberculosis Association · JPOsaka City University · JPNational Institute of Infectious Diseases · JPNiigata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel tuberculosis vaccine to replace BCG has long been desired. However, recent vaccine trials focused on cell-mediated immunity have failed to produce promising results. It is worth noting that most commercially available successful vaccines rely on humoral immunity. To establish a basic understanding of humoral immunity against tuberculosis, we analyzed and evaluated longitudinal levels and avidity of immunoglobulin to various tuberculosis antigens compared with bacterial and clinical parameters during treatment. We found that levels of IgG antibodies against HrpA and HBHA prior to treatment exhibited a positive correlation with bacterial burden. Analysis of changes in CRP during treatment revealed an association with high levels of specific IgG and IgA antibodies against mycobacterial antigens. Levels of CRP prior to treatment were negatively associated with IgG avidity to CFP-10 and MDP1 and IgA avidity to HrpA, while IgA avidity to MDP1 and Acr exhibited a negative correlation with CRP levels after 60 days of treatment. These results may provide insight for the development of a novel tuberculosis (TB) vaccine candidate to induce protective humoral immunity against tuberculosis.

Indexed as

AdultAgedAged, 80 and overAntibodies, BacterialAntigens, BacterialFemaleHumansImmunity, HumoralLongitudinal StudiesMaleMiddle AgedMycobacterium tuberculosisTuberculosisTuberculosis VaccinesAntibodies, BacterialAntigens, BacterialTuberculosis Vaccines

Identifiers

PMID30069487
PMCPMC6057312
OpenAlexW2811500378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.